29: Management of Newly Diagnosed Diabetic Pt- Dodge Flashcards

1
Q

which type of DM has high c peptide initially?

A

type 2 DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

which type of DM has more genetic effect?

A

type 2 DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

prediabetes/ increased risk of diabetes/ intermediate hyperglycemia lab values

A
  • fasting glucose 100-125
  • glucose tolearance 140-199
  • HA1C 5.7 - 6.4%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

DM diagnostic lab values

A
  • fasting glucose greater than 126
  • glucose tolerance greater than 200
  • random blood glucose greater than 200
  • H1AC greater than 6.5%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

tx for A1c less than 7.5%

A

lifestyle and dietary changes if motivated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

tx for A1C 7.6-8.9%

A

monotherapy with metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

tx for A1C greater than 9%

A

recommend treatemtn with two oral agents or insulin monotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

tx for A1C 10-12%

A

strong recommendation for insulin therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

tx for A1C 10-12% with ketosis and/or weight loss

A

insulin therapy required ***

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

lifestyle modification recommendations

A

150 minutes/wk of moderate-intesnstiy cardio

3X/wk no more than 2 days off in between

resistance training at least twice per week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

_______ most important factor in reducing the A1C, some estimate a 0.5-1.0% decrease

A

weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

treatment goals

A

A1C less than 7%

fasting glucose 70-130

peak post-eating glucose less than 180

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

initial oral mono-therapy for type 2 DM

A

metformin

decreases glucose production by liver and increases peripheral insulin sensitivity

start at 500 mg once or twice daily, double every week if tolerated by pt until goal of 1000mg twice daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

contraindications for metformin

A

CHF
chronic hypoxia
pregnancy

stop if creatinine greater than 1.5 in men of 1.4 in women (kidney issues)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

stimulate insulin secretion by pancreas beta cells, decrease micorvascular complications

A

sulfonylureas (glyburide, glipizide, glimepiride)

contra for preggers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

sensitize muscle, fat, hepatocytes to insulin

A

thiazolidinediones (pioglitazone)

increased risk of fluid retention - contra for CHF

risk bladder cancer

17
Q

stimulate beta cells, mealtime dosing

A

glitinides

(nateglinide, repaglinide)

cause increased weight gain

18
Q

prevent absorption of simple sugars in gut

A

apha-glucosidase inhibitors (acarbose)

glatulence and GI side effects

19
Q

DPP-4 degrades incretin which stimulates insulin secretion

A

DPP4 inhibitors (sitagliptin)

pancreatitis, angioedema, urticaria

20
Q

increase insulin and decrease glucagon, increase satiety

A

GP1 receptor antagonist (exanatide)

hypoglycemia in combo, can cause weight LOSS

21
Q

block glucose reabsorption in kidney

A

sodium-glucose cotransporter 2 inhibitors

SGLTS2i (canagliflozin)

can cause dehydration
do not use in CKD

22
Q

insulin therapy for type 1 DM

A
  • insulin required

- start at 0.5 units/kg/day

23
Q

insulin therapy for type 2 DM

A
  • insuliln may be required
  • start at 0.1-0.2 units/kg/day
  • goal to get morning fasting glucose less than 130
  • if A1C not controlled, add prandail short acting insulin
24
Q

two options for type 1 DM insulin therapy

A

basal long acting insulin and prandial short acting insulin

continuous infusion short acting insulin via pump

25
Q

lispro
aspart
glulisine

A

short acting insulin

26
Q

glargine
detemir
degludec

A

longer acting insulin

27
Q

increased intracellular glucose leads to formation of …

A

AGEs

bind cell surface receptors, non enzymatic glycosylation

accelerate athersclerosis, promote glomerular dysfucntion, reduce NO synthesis, endothelial dysfunction

28
Q

DM =

A

coronary hear disease equivalent

increased cardiovascular disease CHF, MI, PAD, CHD

29
Q

goal blood pressure for diabetes

A

130/80

30
Q

when would you want to add statin therapy?

A

10 yr risk less than 7.5% give moderate intensity

high intensity if greater than 7.5% risk (atorvastatin, rosuvastatin)

31
Q

proliferative v. non-proliferative retinopathy?

increased risk in african american and hispanic pts

86% type I, 40% type II will develop a retinopathy

A

neovascularization due to hypoxemia - new vessels rupture easier = hemorrhage. hemorrhage leads to aqueous fibrosis and eventual retinal detachment

vascular micro aneurysms, blot hemorrhages, cotton-wool spots. retinal ischemia via change in retinal blood flow

32
Q

when do you need opthamology exam?

A

at diagnosis of type II

w/i 5 yrs of onset of type 1 DM

followed by annual eye exmas

33
Q

when do you need to measure urine albumin:Cr ratio annually?

A
  • at dx of type 2 or w/i 5 yrs of type 1

if greater than 30 mg/g –> use ACEi or ARB to reduce progression of proteinuria and decrease risk of ESRD

34
Q

ADA recommends yearly comprehensive foot exam ?

A
  • at time of dx of type 2 DM

- at 5 yrs after onset of type 1 DM

35
Q

what can be used to promote gastric emptying?

A

dopamine antagonists such as metoclopramide

36
Q

__ of type 2 DM patients will develop foot ulcer

A

15%

most often of the great toe of MTP

37
Q

velvet like discoloration of the neck.axilla

A

acanthosis nigricans

severe insulin resistance